Regeneron Pharmaceuticals Inc

REGN: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|t?LOCK|?<F^CLOCK|@&#?PH

Regeneron Earnings: More Clarity on Timeline for Eylea HD Approval Expansion

Regeneron Pharmaceuticals' third-quarter revenue grew 1% year on year, as growth in Dupixent revenue offset declines in the Eylea franchise. US sales of original-dose Eylea fell 41% year on year and 10% sequentially, while US sales of Eylea HD increased 10% year on year and sequentially.

Sponsor Center